Abstract Details
|
Activity Number:
|
208
|
|
Type:
|
Invited
|
|
Date/Time:
|
Monday, August 5, 2013 : 2:00 PM to 3:50 PM
|
|
Sponsor:
|
Biopharmaceutical Section
|
| Abstract - #307247 |
|
Title:
|
An Overview of Current State of Bayesian Methods in Medical Product Development
|
|
Author(s):
|
Fanni Natanegara*+ and Beat Neuenschwander
|
|
Companies:
|
Eli Lilly and Company and Novartis Pharma AG
|
|
Keywords:
|
Bayesian ;
DIA ;
Education ;
medical product development
|
|
Abstract:
|
Bayesian applications in medical product development have gained popularity in the last few years. Despite many successes, the application across the various areas of medical product development has been modest. The DIA Bayesian Scientific Working Group (BSWG), which includes representatives from industry, regulatory, and academia, has a vision to ensure Bayesian methods are well-understood, accepted, and broadly utilized across medical product development to improve decision making and enhance patient outcomes. The focus of this session is on the recent effort of the DIA BSWG Education sub-team including results from an industry-wide Bayesian survey and recommendations from the sub-team on how to improve the progress on Bayesian application in medical product development.
|
Authors who are presenting talks have a * after their name.
Back to the full JSM 2013 program
|
2013 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Copyright © American Statistical Association.